Bethanechol Chloride

CHEMBL1768 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
196.7 g/mol
LogP
Phase
4

The chloride salt form of bethanechol, used to treat non-obstructive urinary retention and neurogenic bladder by stimulating muscle contractions. It acts on muscarinic receptors to promote bladder emptying and may also be used for certain gastrointestinal motility issues. Side effects can include abdominal cramps, sweating, and low blood pressure.

Molecular Weight

196.6700 g/mol

TPSA

52.30 Ų

Therapeutic Areas

Mechanism of Action

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C[N+](C)(C)C)OC(N)=O.[Cl-]

InChI

InChI=1S/C7H16N2O2.ClH/c1-6(11-7(8)10)5-9(2,3)4;/h6H,5H2,1-4H3,(H-,8,10);1H

Molecular Formula

C7H17ClN2O2

HBD / HBA

1 / 3

Rotatable Bonds

4

Heavy Atoms

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The chloride salt form of bethanechol, used to treat non-obstructive urinary retention and neurogenic bladder by stimulating muscle contractions. It acts on muscarinic receptors to promote bladder emptying and may also be used for certain gastrointestinal motility issues. Side effects can include abdominal cramps, sweating, and low blood pressure.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Bethanechol Chloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1768. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 11548. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.